News | Image Guided Radiation Therapy (IGRT) | June 18, 2018

Elekta Unity High-Field MR-Linac Receives CE Mark

New MRI-guided, linear accelerator-based radiation therapy system will now be implemented clinically in Europe

Elekta Unity High-Field MR-Linac Receives CE Mark

June 18, 2018 — Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark, clearing the technology for commercial sales and clinical use in Europe.

According to Elekta, Unity has the potential to transform how clinicians treat cancer by enabling the delivery of the radiation dose while simultaneously visualizing the tumor and surrounding healthy tissue with high-quality MR images. Unity also integrates advanced tools that allow clinicians to adapt the patient's treatment to this current anatomical information.

"Unity is a tremendous innovation in patient care, one that enables a scan-plan-treat approach to developing tailored regimens that should yield substantive clinical benefits," said Bas Raaymakers, Ph.D., professor of experimental clinical physics in the Department of Radiotherapy at University Medical Center (UMC) Utrecht, The Netherlands. UMC Utrecht is a founding member of the Elekta MR-linac Consortium and the inventor of the high-field MR-linac concept. Raaymakers added, "I am thrilled that our vision of personalized radiation therapy is becoming a clinical reality."

Unity employs a premium high-field, diagnostic-quality (1.5 Tesla) MRI that provides unparalleled image clarity, according to Elekta. This gives clinicians greater flexibility in their approach to radiation therapy and ensures that each patient receives optimal care based on individual tumor characteristics. Unity integrates MRI, linear accelerator technologies and advanced treatment planning into a single platform, allowing clinicians to see and track difficult-to-visualize soft tissue anatomies while radiation dose is being delivered. This new technology addresses an unmet need in cancer therapy, enabling clinicians to confidently see and track the target during treatment and respond accordingly, personalizing therapy for each patient every time they are treated.

Elekta Unity has CE mark but is not available for commercial distribution or sale in the U.S.

For more information: www.elekta.com

Related Radiation Therapy Content

Technological Improvements in Radiation Therapy

University Medical Centre Utrecht Treats First Cancer Patient With Elekta Unity MR-Guided Linear Acclerator

MRI-guided Radiation Therapy

VIDEO: The Future of Radiation Oncology

Related Content

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Hyperfine Research, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the world’s first bedside Magnetic Resonance Imaging (MRI) system

Hyperfine's point-of-care MRI wheels directly to the patient’s bedside, plugs into a standard electrical wall outlet, and is controlled via a wireless tablet. Photo courtesy of Business Wire

News | Magnetic Resonance Imaging (MRI) | February 12, 2020
February 12, 2020 — Hyperfine Research, Inc. announced that i
The magnetic resonance imaging (MRI) contrast agents market is expected to grow rapidly

Image courtesy of GE Healthcare

News | Magnetic Resonance Imaging (MRI) | February 11, 2020
February 11, 2020 — The magnetic resonance imaging (MRI) contrast agents market is expected to grow rapidly in the fo
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
February 6, 2020 — University of Texas at Dallas researchers
Qynapse, a medical technology company, announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its QyScore software
News | Information Technology | February 04, 2020
February 4, 2020 — Qynapse, a medical technology company, anno